

## Case Report Section

Paper co-edited with the European LeukemiaNet

# Translocation t(X;20)(q13;q13.3) as a secondary chromosome abnormality in a patient with 5q-: a case report

Carlos Augusto Figueiredo Correia, Juliana Lino Rodrigues de Matos, Cristina Alonso Ratis, Silvia Helena A Figueira, Renata Kiyomi Kishimoto, Elvira D Rodrigues Pereira Velloso

Laboratorio de Tecnicas Especiais- Citogenetica do Hospital Israelita Albert Einstein, Sao Paulo, Brazil and Hospital das Clinicas da Universidade Federal de Minas Gerais, Minas Gerais, Brazil (CAF), Hemomed, Sao Paulo, Brazil (JLR), Laboratorio de Tecnicas Especiais- Citogenetica do Hospital Israelita Albert Einstein, Sao Paulo, Brazil (CA, SHAF, RKK, EDR)

Published in Atlas Database: January 2013

Online updated version : <http://AtlasGeneticsOncology.org/Reports/tX20q13q13FigueiredoID100066.html>  
DOI: 10.4267/2042/51053

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 2013 Atlas of Genetics and Cytogenetics in Oncology and Haematology

### Clinics

#### Age and sex

76 years old female patient.

#### Previous history

Preleukemia. Low risk myelodysplastic syndrome (refractory anemia) diagnosed 32 months before (December, 2009). No previous malignancy, no inborn condition of note.

#### Organomegaly

No hepatomegaly, no splenomegaly, no enlarged lymph nodes, no central nervous system involvement.

### Blood

**WBC:**  $2.7 \times 10^9/l$

**HB:** 8.5g/dl

**Platelets:**  $146 \times 10^9/l$

**Blasts:** 0%

**Bone marrow:** 5% (Global normocellularity, with erythroid and megakaryocytic hyperplasia and megakaryocytic dysplasia (no-lobated megakaryocytes suggestive of 5q- Syndrome), less than 5% of myeloblasts and 23% of ring sideroblasts.)

### Cyto-Pathology Classification

#### Cytology

Myelodysplastic Syndrome - Refractory anemia with ring sideroblasts (FAB classification).

#### Diagnosis

Myelodysplastic Syndrome - Refractory citopenia with multilineage dysplasia and ringed sideroblasts (WHO classification).

### Survival

**Date of diagnosis:** 08-2012

**Treatment:** Erythropoietin

**Complete remission:** no


**Treatment related death:** no

**Relapse:** no

**Status:** Alive

**Last follow up:** 09-2012

**Survival:** 1 month from the cytogenetic abnormality detection, 30 months from the MDS diagnosis.months



Partial G-banded karyotypes showing the del(5)(q13q31) and the t(X;20)(q13;q13.3)

## Karyotype

**Sample:** Bone marrow

**Culture time:** 24 and 48 hours without stimulating agents

**Banding:** GTG

### Results

46,XX,del(5)(q13q31)[1]/46,X,t(X;20)(q13;q13.3),del(5)(q13q31)[11]/46,XX[8]

### Karyotype at Relapse

not done

## Comments

The band Xq13 is frequently involved in rearrangements seen in hematological malignancy. The structural rearrangement idic(X)(q13) is associated with the myelodysplastic syndrome with ringed sideroblasts and this region is difficult for mapping because it is rich in complex repeats with subregional inversions and high concentration of LINE repeats (boosters of X-inactivation). The chromosome 20q interstitial deletions are well established nonrandom abnormalities in myeloid disorders, particularly in polycythemia vera and myelodysplasia. Very few cases of translocations involving chromosome 20 have been reported in hematological malignancy. The band 20q13 is rich in cancer genes and translocation involving this region has been reported in cases of acute myeloid leukemia. One study shows that breakpoints of X chromosomes associated with myelodysplasia were located in a region of 450 kb next to the gene XIST (Xq13). Another study demonstrated that a critical event in

myelodysplasia is loss of tumor suppressor genes present on the long arm of chromosome 20. This suppression can occur when a potential cryptic deletion is associated with a translocation. This phenomenon generates a second mechanism causing inactivation of the X chromosome and derivative 20 resulting loss of function of tumor suppressor genes.

Seven cases of t(X;20)(q13;q13) were described in literature; all affecting women over the age of 57 with myeloid disorders.

We report the detection, by conventional cytogenetic methods, the t(X;20)(q13;q13.3) in one female patient with myelodysplastic syndrome subtype Refractory citopenia with multilineage dysplasia and ringed sideroblasts (classification WHO).

Although this translocation was described as a primary clonal chromosome abnormality, in this case the t(X;20) seems to be a secondary chromosome abnormality following a deletion 5q.

## References

Dewald GW, Pierre RV, Phyliky RL. Three patients with structurally abnormal X chromosomes, each with Xq13 breakpoints and a history of idiopathic acquired sideroblastic anemia. *Blood*. 1982 Jan;59(1):100-5

Dewald GW, Brecher M, Travis LB, Stupca PJ. Twenty-six patients with hematologic disorders and X chromosome abnormalities. Frequent idic(X)(q13) chromosomes and Xq13 anomalies associated with pathologic ringed sideroblasts. *Cancer Genet Cytogenet*. 1989 Oct 15;42(2):173-85

Roulston D, Espinosa R 3rd, Stoffel M, Bell GI, Le Beau MM. Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. *Blood*. 1993 Dec 1;82(11):3424-9

Michaux L, Wlodarska I, Mecucci C, Hernandez JM, Van Orshoven A, Michaux JL, Van den Berghe H. Characterization by chromosome painting of balanced and unbalanced X chromosome translocations in myelodysplastic syndromes. *Cancer Genet Cytogenet.* 1995 Jul 1;82(1):17-22

McDonnell N, Ramser J, Francis F, Vinet MC, Rider S, Sudbrak R, Riesselman L, Yaspo ML, Reinhardt R, Monaco AP, Ross F, Kahn A, Kearney L, Buckle V, Chelly J. Characterization of a highly complex region in Xq13 and mapping of three isodicentric breakpoints associated with preleukemia. *Genomics.* 2000 Mar 15;64(3):221-9

O'Reilly J, Crawford J, Uzaraga J, Cannell P. Translocation (X;20) involving the inactive X chromosome in a patient with

myeloproliferative disorder. *Cancer Genet Cytogenet.* 2005 Apr 1;158(1):81-3

Reddy KS, Richkind K, Ross M, Seirra R. Translocation (X;20)(q13;q13.3): a nonrandom abnormality in four patients with myeloid disorders. *Cancer Genet Cytogenet.* 2005 Feb;157(1):70-3

---

*This article should be referenced as such:*

Figueiredo Correia CA, Rodrigues de Matos JL, Alonso Ratis C, Figueira SHA, Kishimoto RK, Rodrigues Pereira Velloso ED. Translocation t(X;20)(q13;q13.3) as a secondary chromosome abnormality in a patient with 5q-: a case report. *Atlas Genet Cytogenet Oncol Haematol.* 2013; 17(7):513-515.

---